S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors
ifosfamide
Neoplasias Meningeas+14
+ Miosarcoma
+ Neoplasias
Estudio de Tratamiento
Resumen
Fecha de inicio: 1 de julio de 1998
Fecha en la que se inscribió al primer participante.OBJECTIVES: Estimate failure free survival, overall survival, and response in patients with residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma, hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide. Evaluate toxicities of ifosfamide in this patient population. OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months thereafter. PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 7 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Tratamiento
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.A partir de 18 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
DISEASE CHARACTERISTICS: Histologically proven recurrent or unresectable: Malignant meningioma Intracranial hemangiopericytoma Primary central nervous system sarcoma, including: Fibrosarcoma Rhabdomyosarcoma Chondrosarcoma Leiomyosarcoma Measurable or evaluable disease on CT or MRI scan Persistent disease following biopsy or incomplete resection OR Recurrent disease following complete resection No benign meningioma No prior or current systemic sarcoma PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm^3 Absolute granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Not specified Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No myocardial infarction within the past 3 months No active angina No unstable heart rhythms No congestive heart failure Other: HIV negative No allergy to study drugs No serious concurrent medical or psychiatric illness No uncontrolled peptic ulcer disease No prior malignancy within past 5 years except adequately treated: Basal or squamous cell carcinoma of the skin Carcinoma in situ of the cervix Not pregnant or nursing Effective contraception required of fertile patients PRIOR CONCURRENT THERAPY: Recovered from toxic effects of prior therapy and/or from postoperative complications Biologic therapy: Not specified Chemotherapy: No prior ifosfamide No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy (except estrogen replacement therapy) Corticosteroids allowed if dose is stable or decreasing Radiotherapy: At least 4 weeks since prior radiotherapy Progressive disease following radiation required No concurrent radiotherapy Surgery: See Disease Characteristics
Plan de Estudio
Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.Un solo grupo de intervención está designado en este estudio
0% de probabilidad de ser asignado al grupo placebo
Grupos de Tratamiento
Grupo I
ExperimentalCentros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene 70 ubicaciones
CCOP - Scottsdale Oncology Program
Scottsdale, United StatesAbrir CCOP - Scottsdale Oncology Program en Google MapsCity of Hope Comprehensive Cancer Center
Duarte, United StatesVeterans Affairs Medical Center - Palo Alto
Palo Alto, United StatesStanford University Medical Center
Stanford, United States